The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients

The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients

BackgroundHemodialysis patients are at high risk for severe COVID-19. SARS-CoV-2 vaccination related safety and immunogenicity data in these patients are rare.MethodsIn this observational study SARS-CoV-2-seronegative hemodialysis patients were vaccinated with two doses of the Pfizer/BioNTech mRNA-B...

Full description

Bibliographic Details
Main Authors: Emanuel Zitt, Tamara Davidovic, Judith Schimpf, Armin Abbassi-Nik, Beatrix Mutschlechner, Hanno Ulmer, Magdalena A. Benda, Hannelore Sprenger-Mähr, Thomas Winder, Karl Lhotta
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Immunology
Subjects:
BNT162b2
COVID-19
hemodialysis
mRNA vaccine
SARS-CoV-2
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.704773/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.704773/full

Similar Items